Please provide your email address to receive an email when new articles are posted on . Retinoschisis is a nonprogressive degenerative splitting of the neurosensory retina, most often at the outer ...

Please provide your email address to receive an email when new articles are posted on . Atsena Therapeutics has dosed the first patient in its open-label, phase 1/2 LIGHTHOUSE study to evaluate the ...

Juvenile Retinoschisis is an inherited disease diagnosed in childhood that causes progressive loss of central and peripheral (side) vision due to degeneration of the retina. Juvenile retinoschisis, ...

DURHAM, N.C., March 12, 2025 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness ...

June 8, 2007 — The US Food and Drug Administration (FDA) has granted orphan drug designation for AMT 011 for the treatment of lipoprotein lipase deficiency, axitinib for the treatment of pancreatic ...

DURHAM, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, ...

DURHAM, N.C., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent ...

RETINOSCHISIS. IT IS A BATTLE HIS TEAMMATES AND COMMUNITY ARE FIGHTING WITH M. SPOTTING WINTERSET HIGH SCHOOL WRESTLER KASEN COCHRAN DURING THE DUAL TEAM STATE CHAMPIONSHS IPIS NOT DIFFICU.LT HE IS ...

Part A results demonstrated efficacy and safety; ATSN-201 on track to be first gene therapy and one-time treatment for XLRS DURHAM, N.C., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a ...

(MENAFN- GlobeNewsWire - Nasdaq) Marks third FDA designation for ATSN-201, which has also received Rare Pediatric Disease Designation and Orphan Drug Designation DURHAM, N.C., March 12, 2025 (GLOBE ...